Document is current

Article History

Received: 23 November 2021

Accepted: 16 May 2022

First Online: 25 May 2022

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ontario Cancer Research Ethics Board (OCREB).

: This article does not contain any studies with animals performed by any of the authors.

: Participation and completion of the survey implied consent to participate in the study.

: Participation and completion of the survey implied consent to publication of aggregate survey findings.

: SMG reports receipt of honorarium from Novartis for insights on management of breast cancer patients. BH and MC report consulting fees from Cornerstone Research, outside the submitted works. All other authors declare no competing interests. KEE is a co-founder of and SVP at Replica Analytics, a spin-off company from the University of Ottawa that develops synthetic data generation software. LM is an employee of Replica Analytics. GRP reports consulting fees from Merck and Profound Medical, honorarium for DSMB membership from Takeda and has a close family member who works for Roche Canada and owns stock in Roche, all outside the submitted works.